Merit Medical launched the Prelude Wave™ Hydrophilic Sheath Introducer, enhancing radial access procedures with superior securement technology.
Quiver AI Summary
Merit Medical Systems, Inc. has announced the US launch of the Prelude Wave™ Hydrophilic Sheath Introducer featuring SnapFix™ Securement Technology, aimed at enhancing radial access procedures. This innovative sheath, part of Merit's Access portfolio, is designed to minimize risks such as arterial spasm and occlusion, which can affect patient comfort and outcomes. The Prelude Wave boasts a low-profile design, superior lubricity, and a unique securement feature, offering significant advantages over competitors. By addressing physician challenges during radial procedures, the Prelude Wave aims to improve patient experiences and outcomes. Merit continues to advance its product offerings and support a radial-first approach in vascular access technology.
Potential Positives
- Announcement of the commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology, showcasing Merit's commitment to innovation in healthcare technology.
- The Prelude Wave's design features are intended to help reduce arterial spasm and occlusion, potentially improving patient outcomes during radial access procedures.
- The product claims superior performance in terms of lubricity, resistance to kinking, and ease of insertion compared to its leading competitor, which may enhance market competitiveness.
- Merit's focused strategy on addressing clinical challenges in radial procedures may strengthen relationships with healthcare professionals and bolster sales in the interventional cardiology sector.
Potential Negatives
- The mention of reported issues with securement devices utilized in 30% of cases could indicate potential reliability problems with current offerings, which may raise concerns about the Prelude Wave's acceptance in the market.
- The acknowledgment that arterial spasm and occlusion can still occur in a significant percentage of patients despite the new product suggests that the Prelude Wave may not fully resolve existing clinical challenges.
- The press release's references to regulatory and operational risks, indicating that actual results may differ materially from anticipated results, may create uncertainty regarding the product's market performance.
FAQ
What is the Prelude Wave™ Hydrophilic Sheath Introducer?
The Prelude Wave is a new hydrophilic sheath introducer designed for enhanced radial access procedures and improved patient outcomes.
How does SnapFix™ Securement Technology work?
SnapFix technology provides superior adhesive strength, stabilizing the sheath during procedures and potentially reducing complications.
What are the benefits of radial access procedures?
Radial access offers various advantages, including a lower risk of complications compared to traditional femoral procedures and enhanced patient comfort.
How does Prelude Wave compare to competitors?
Prelude Wave features twice the lubricity, greater resistance to kinking, and requires 40% less insertion force than leading competitors.
What is Merit Medical's commitment to innovation?
Merit Medical strives to enhance its Access portfolio through innovative products and strategic acquisitions, focusing on improving patient care and outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MMSI Insider Trading Activity
$MMSI insiders have traded $MMSI stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $MMSI stock by insiders over the last 6 months:
- FRED P. LAMPROPOULOS (President and CEO) has made 0 purchases and 8 sales selling 74,719 shares for an estimated $7,436,213.
- BRIAN G. LLOYD (CHIEF LEGAL OFFICER, SECRETARY) has made 0 purchases and 2 sales selling 55,000 shares for an estimated $5,574,500.
- RAUL JR. PARRA (CFO AND TREASURER) has made 0 purchases and 3 sales selling 32,993 shares for an estimated $3,208,794.
- F. ANN MILLNER sold 21,250 shares for an estimated $2,049,987
- MICHEL JAMES VOIGT (CHIEF HUMAN RESOURCES OFFICER) sold 13,809 shares for an estimated $1,376,481
- NEIL PETERSON (CHIEF OPERATING OFFICER) has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,047,650.
- STEPHEN C. EVANS sold 5,000 shares for an estimated $526,550
- DAVID FLOYD sold 3,515 shares for an estimated $330,972
- MICHAEL R. MCDONNELL has made 0 purchases and 2 sales selling 3,500 shares for an estimated $330,417.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MMSI Hedge Fund Activity
We have seen 169 institutional investors add shares of $MMSI stock to their portfolio, and 199 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAVERICK CAPITAL LTD added 1,272,511 shares (+inf%) to their portfolio in Q1 2025, for an estimated $134,517,137
- CHANNING CAPITAL MANAGEMENT, LLC removed 681,794 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $72,072,443
- FMR LLC added 492,816 shares (+23.7%) to their portfolio in Q1 2025, for an estimated $52,095,579
- JPMORGAN CHASE & CO added 438,421 shares (+96.6%) to their portfolio in Q1 2025, for an estimated $46,345,483
- BRYN MAWR CAPITAL MANAGEMENT, LLC removed 370,722 shares (-99.4%) from their portfolio in Q1 2025, for an estimated $39,189,022
- AMERIPRISE FINANCIAL INC added 345,070 shares (+109.4%) to their portfolio in Q1 2025, for an estimated $36,477,349
- ARROWMARK COLORADO HOLDINGS LLC removed 281,022 shares (-22.1%) from their portfolio in Q1 2025, for an estimated $29,706,835
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MMSI Analyst Ratings
Wall Street analysts have issued reports on $MMSI in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 07/31/2025
- Barrington Research issued a "Outperform" rating on 07/31/2025
- Raymond James issued a "Outperform" rating on 07/31/2025
- Wells Fargo issued a "Overweight" rating on 07/31/2025
- Needham issued a "Buy" rating on 07/18/2025
- Canaccord Genuity issued a "Buy" rating on 05/21/2025
- Baird issued a "Outperform" rating on 04/25/2025
To track analyst ratings and price targets for $MMSI, check out Quiver Quantitative's $MMSI forecast page.
$MMSI Price Targets
Multiple analysts have issued price targets for $MMSI recently. We have seen 8 analysts offer price targets for $MMSI in the last 6 months, with a median target of $106.5.
Here are some recent targets:
- Jayson Bedford from Raymond James set a target price of $102.0 on 07/31/2025
- Jason Bednar from Piper Sandler set a target price of $105.0 on 07/31/2025
- Larry Biegelsen from Wells Fargo set a target price of $100.0 on 07/31/2025
- Michael Petusky from Barrington Research set a target price of $103.0 on 07/31/2025
- Mike Matson from Needham set a target price of $108.0 on 07/18/2025
- Jon Young from Canaccord Genuity set a target price of $112.0 on 05/21/2025
- David Rescott from Baird set a target price of $110.0 on 04/25/2025
Full Release
SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology.
The Prelude Wave is the latest innovation in Merit’s comprehensive Access portfolio, which includes a wide range of dilators, micro-access systems, sheath introducers, and guide sheaths. A low-profile, hydrophilic sheath with best-in-class insertion and sheath retention, the Prelude Wave with SnapFix technology is designed with features which may aid in the reduction of arterial spasm and occlusion as physicians perform radial access procedures.
Radial access offers many well-documented benefits compared to the femoral approach, 1 but there remain opportunities to improve patient outcomes, as radial artery spasm (narrowing) and occlusion (blockage) can still occur.
Radial artery spasm is reported in up to 20% of patients, 2 and approximately 4.6% will have a radial artery occlusion, 3 both of which can lead to patient discomfort and other complications. 4,5 Sheath features, such as a hydrophilic coating, a low profile, and tapered transitions have been shown to help reduce the risks of radial artery spasm and occlusion as well as improve patient comfort. 1, 6
In addition, securement devices utilized to stabilize hydrophilic sheaths during procedures have been linked to reported issues in 30% of cases, leading to procedural inefficiency. 7 A securement device specifically developed for sheaths may help alleviate the challenges physicians face.
To meet these clinical needs, Merit innovated the Prelude Wave, a next-generation sheath with a unique securement feature. Compared to the leading competitor, the Prelude Wave offers twice the lubricity, twice the resistance to buckling and kinking, and requires 40% less insertion force. 8 A first of its kind, SnapFix technology provides twice the adhesive strength, with physicians rating its performance and ease of use superior to the leading competitor. 8
Learn more about the Prelude Wave with SnapFix Technology.
“Prelude Wave addresses challenges interventionalists see when performing radial procedures,” said Morton Kern, MD, MSCAI, FACC, FAHA, Interventional Cardiologist at Veterans Administration Long Beach Health Care System in Long Beach, CA, and a consultant of Merit. “A sheath and securement solution that may help minimize these risks, while also offering strong radial access performance, provides physicians with a meaningful product option that creates a better treatment experience for patients.”
To further support a radial-first approach, Merit has tailored its portfolio with solutions that complement existing products, designed to address physicians’ toughest clinical challenges. A recent example of this was Merit’s acquisition of StatSeal®, a patented hemostatic sealant used to protect access sites, as seen in radial procedures.
“Whether by design or acquisition, we always strive to advance innovation in our Access portfolio, providing our healthcare partners with solutions that support data-driven approaches to treatment,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “The Prelude Wave with SnapFix Technology is a superior product built to champion radial procedures, manufactured with features designed to aid in minimizing common vascular access challenges. We’re proud to continue offering radial technology advancements for physicians and their patients.”
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
Any forward-looking statements set forth in this release are subject to risks and uncertainties such as those described in Merit's filings with the U. S. Securities and Exchange Commission (“SEC”). For a further discussion of the risks and uncertainties which may affect Merit’s business, operations and financial condition, see Part I, Item 1A, “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, Part II, Item 1A, “Risk Factors” in Merit’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC and Merit’s other filings with the SEC. Actual results will likely differ, and may differ materially, from anticipated results.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 |
[email protected]
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 |
[email protected]
References
- Rathore et al. 2010. “Impact of Length and Hydrophilic Coating of the Introducer Sheath on Radial Artery Spasm during Transradial Coronary Intervention.” JACC Cardiovasc Interv 3, no. 5 (May): 475 ̶ 83. doi: 10.1016/j.jcin.2010.03.009.
- Randall and Boudoulas. “ Reducing Radial Spasm .” Society for Cardiovascular Angiography & Interventions (2024 Sep 19).
- Pitta, Sharma, and Boudoulas. “ Newer Emerging Strategies to Reduce Radial Artery Occlusion: Post-Transradial Catheterization .” Society for Cardiovascular Angiography & Interventions (2025 Jun 19).
- Zus et al. 2024. “Radial Artery Spasm—A Review on Incidence, Prevention and Treatment.” Diagnostics (Basal) 14, no 17 (Aug 29): 1897. doi: 10.3390/diagnostics14171897.
- Tsigkas et al. 2023. “Preventing and Managing Radial Artery Occlusion Following Transradial Procedures: Strategies and Considerations.” J Cardiovasc. Dev Dis. 10, no. 7 (Jun 30): 283. doi: 10.3390/jcdd10070283.
- Mason et al. 2018. “An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement from the American Heart Association.” Cir Cardiovasc Interv 11, no. 9 (Sept): e000035. doi: 10.1161/HCV.0000000000000035.
- Kern et al. 2020. “ Securing the Radial Sheath: An Update on a Pesky but Persistent Little Problem .” Cath Lab Digest (Nov).
- Data on File.